Amubarvimab, previously known as BRII-196 , represents a significant advancement in biopharmaceutical development, particularly concerning its potential to block COVID-19. This engineered agent demonstrates remarkable activity against variant versions of the virus , showing promise for both prophylactic and treatment applications. Early clinical re